Ries, LAG, Melbert, D, Krapcho, M. SEER cancer statistics review, 1975–2004. SEER Web site. Available at: http://seer.cancer.gov/csr/1975_2004/.

Jemal, A, Siegel, R, Ward, E. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.CrossRefGoogle ScholarPubMed

Jemal, A, Siegel, R, Ward, E. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.CrossRefGoogle ScholarPubMed

Diab, SG, Clark, GM, Osborne, CK. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 1999;17:1442–1448.CrossRefGoogle ScholarPubMed

Taylor, IW, Musgrove, EA, Friedlander, ML. The influence of age on the DNA ploidy levels of breast-tumors. Eur J Cancer Clin Oncol. 1983;19:623–628.CrossRefGoogle Scholar

Lyman, GH, Lyman, S, Balducci, L. Age and the risk of breast cancer recurrence. Cancer Control. 1996;3:421–427.Google ScholarPubMed

Honma, N, Sakamoto, G, Akiyama, F. Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, estrogen, and progesterone receptor status. Histopathology. 2003;42:120–127.CrossRefGoogle ScholarPubMed

Adami, HO, Malker, B, Holmberg, L. The relation between survival and age at diagnosis in breast cancer. N Engl J Med. 1986;315:559–563.CrossRefGoogle ScholarPubMed

Holli, K, Isola, J. Effect of age on the survival of breast cancer patients. Eur J Cancer. 1997;33:425–428.CrossRefGoogle ScholarPubMed

Extermann, M, Aapro, M, Bernabei, R. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241–252.CrossRefGoogle Scholar

Balducci, L.Geriatric oncology. Crit Rev Oncol Hematol. 2003;46:211–220.CrossRefGoogle ScholarPubMed

Berry, DA, Cirrincione, C, Henderson, IC. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. J Am Med Assoc. 2006;295: 1658–1667.CrossRefGoogle ScholarPubMed

Gennari, A, Sormani, MP, Pronzato, P. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst. 2008;100:14–20.CrossRefGoogle ScholarPubMed

Pritchard, KI, Shepherd, , O';Malley, FP. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006;354:2103–2111.CrossRefGoogle ScholarPubMed

Hayes, DF, Thor, AD, Dressler, LG. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007;357:1496–1506.CrossRefGoogle ScholarPubMed

Slamon, D, Eiermann, W, Robert, N. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis. Paper presented at: 29th Annual SABCS; December 14-17 2006; San Antonio, Texas.

Pinder, MC, Duan, Z, Goodwin, JS. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808–3815.CrossRefGoogle ScholarPubMed

Hershman, DL, McBride, RB, Eisenberger, A. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:3159–3165.CrossRefGoogle ScholarPubMed

Buyse, M, Loi, S, van't Veer, L. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;98:1183–1192.CrossRefGoogle ScholarPubMed

Paik, S, Shak, S, Tang, G. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826.CrossRefGoogle ScholarPubMed

Paik, S, Tang, G, Shak, S. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–3734.CrossRefGoogle ScholarPubMed

Harris, L, Fritsche, H, Mennel, R. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287– 5312.CrossRefGoogle Scholar

Ravdin, PM, Siminoff, , Davis, GJ. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19:980–991.CrossRefGoogle ScholarPubMed

Pierga, JY, Girre, V, Laurence, V. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast. 2004;13:369–375.CrossRefGoogle ScholarPubMed

Cutuli, B, Aristei, C, Martin, C. Breast-conserving therapy for stage I–II breast cancer in elderly women. Int J Radiat Oncol Biol Phys. 2004;60:71–76.CrossRefGoogle ScholarPubMed

Wazer, , Erban, JK, Robert, NJ. Breast conservation in elderly women for clinically negative axillary lymph nodes without axillary dissection. Cancer. 1994;74:878–883.3.0.CO;2-4>CrossRefGoogle ScholarPubMed

Yancik, R, Ries, LG, Yates, JW. Breast cancer in aging women: a population-based study of contrasts in stage, surgery, and survival. Cancer. 1989;63:976–981.3.0.CO;2-A>CrossRefGoogle Scholar

Singletary, SE, Shallenberger, R, Guinee, VF. Breast cancer in the elderly. Ann Surg. 1993;218:667–671.CrossRefGoogle ScholarPubMed

Bergman, L, Kluck, HM, Leeuwen, FE. The influence of age on treatment choice and survival of elderly breast cancer patients in south-eastern Netherlands: a population-based study. Eur J Cancer. 1992;28A:1475–1480.CrossRefGoogle ScholarPubMed

Leung, JM, Dzankic, S. Relative importance of preoperative health status versus intraoperative factors in predicting postoperative adverse outcomes in geriatric surgical patients. J Am Geriatr Soc. 2001;49:1080–1085.CrossRefGoogle ScholarPubMed

Gagner, M, Franco, D, Vons, C. Analysis of morbidity and mortality rates in right hepatectomy with the preoperative APACHE II score. Surgery. 1991;110:487–492.Google ScholarPubMed

Pope, D, Ramesh, H, Gennari, R. Pre-operative assessment of cancer in the elderly (PACE): a comprehensive assessment of underlying characteristics of elderly cancer patients prior to elective surgery. Surg Oncol. 2006;15:189–197.CrossRefGoogle ScholarPubMed

Sandison, AJ, Gold, DM, Wright, P. Breast conservation or mastectomy: treatment choice of women aged 70 years and older. Br J Surg. 1996;83:994–996.CrossRefGoogle ScholarPubMed

Figueiredo, MI, Cullen, J, Hwang, YT. Breast cancer treatment in older women: does getting what you want improve your long-term body image and mental health?J Clin Oncol. 2004;22:4002–4009.CrossRefGoogle ScholarPubMed

Sweeney, C, Schmitz, KH, Lazovich, D. Functional limitations in elderly female cancer survivors. J Natl Cancer Inst. 2006;98:521–529.CrossRefGoogle ScholarPubMed

Mano, M, Fraser, G, McIlroy, P. Locally advanced breast cancer in octogenarian women. Breast Cancer Res Treat. 2005;89:81–90.CrossRefGoogle ScholarPubMed

Truong, PT, Bernstein, V, Wai, E. Age-related variations in the use of axillary dissection: a survival analysis of 8038 women with T1-ST2 breast cancer. Int J Radiat Oncol Biol Phys. 2002;54:794–803.CrossRefGoogle ScholarPubMed

Wazer, , Schmidt-Ullrich, RK, Ruthazer, R. The influence of age and extensive intraductal component histology upon breast lumpectomy margin assessment as a predictor of residual tumor. Int J Radiat Oncol Biol Phys. 1999;45:885–891.CrossRefGoogle ScholarPubMed

Martelli, G, Miceli, R, Costa, A. Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: fifteen-year results of a prospective study. Cancer. 2008;112: 481–488.CrossRefGoogle ScholarPubMed

Mandelblatt, JS, Edge, SB, Meropol, NJ. Sequelae of axillary lymph node dissection in older women with stage 1 and 2 breast cancer. Cancer. 2002;95:2445–2454.CrossRefGoogle Scholar

Gennari, R, Rotmensz, N, Perego, E. Sentinel node biopsy in elderly breast cancer patients. Surg Oncol. 2004;13:193–196.CrossRefGoogle ScholarPubMed

Lyman, GH, Giuliano, AE, Somerfield, MR. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–7720.CrossRefGoogle Scholar

Hughes, KS, Schnaper, , Berry, D. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–977.CrossRefGoogle ScholarPubMed

Rudenstam, CM, Zahrieh, D, Forbes, JF. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol. 2006;24:337–344.Google Scholar

Vinh-Hung, V, Verschraegen, C. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004;96:115–121.CrossRefGoogle ScholarPubMed

Deutsch, M. Radiotherpay after lumpectomy for breast cancer in very old women. Am J Clin Oncol. 2002;25:48–49.CrossRefGoogle Scholar

Veronesi, U, Luini, A, Del Vecchio, M. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med. 1993;328:1587–1591.CrossRefGoogle ScholarPubMed

Smith, BD, Gross, CP, Smith, GL. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst. 2006;98:681–690.CrossRefGoogle ScholarPubMed

Maher, M, Campana, F, Mosseri, V. Breast cancer in elderly women: a retrospective analysis of combined treatment with tamoxifen and once-weekly irradiation. Int J Radiat Oncol Biol Phys. 1995;31:783–789.CrossRefGoogle ScholarPubMed

Ortholan, C, Hannoun-Levi, JM, Ferrero, JM. Long-term results of adjuvant hypofractionated radiotherapy for breast cancer in elderly patients. Int J Radiat Oncol Biol Phys. 2005;61:154–162.CrossRefGoogle ScholarPubMed

Courdi, A, Ortholan, C, Hannoun-Levi, JM. Long-term results of hypofractionated radiotherapy and hormonal therapy without surgery for breast cancer in elderly patients. Radiother Oncol. 2006;79:156–161.CrossRefGoogle ScholarPubMed

Hannoun-Levi, JM, Courdi, A, Marsiglia, H. Breast cancer in elderly women: is partial breast irradiation a good alternative?Breast Cancer Res Treat. 2003;81:243–251.CrossRefGoogle ScholarPubMed

Dunser, M, Haussler, B, Fuchs, H. Tumorectomy plus tamoxifen for the treatment of breast cancer in the elderly. Eur J Surg Oncol. 1993;19:529–531.Google ScholarPubMed

Martelli, G, DePalo, G, Rossi, N. Long-term follow-up of elderly patients with operable breast cancer treated with surgery without axillary dissection plus adjuvant tamoxifen. Br J Cancer. 1995;72:1251–1255.CrossRefGoogle ScholarPubMed

Sader, C, Ingram, D, Hastrich, D. Management of breast cancer in the elderly by complete local excision and tamoxifen alone. Aust N Z J Surg. 1999;69:790–793.CrossRefGoogle ScholarPubMed

Geiger, AM, Thwin, SS, Lash, TL. Recurrences and second primary breast cancers in older women with initial early-stage disease. Cancer. 2007;109:966–974.CrossRefGoogle ScholarPubMed

Hughes, KS, Schnaper, , Berry, D. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Eng J Med. 2004;351:971.CrossRefGoogle ScholarPubMed

Fisher, B, Dignam, J, Wolmark, N. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993–2000.CrossRefGoogle ScholarPubMed

Peyrade, F, Frenay, M, Etienne, MC. Age-related difference in tamoxifen disposition. Clin Pharmacol Ther. 1996;59:401–410.CrossRefGoogle ScholarPubMed

Houghton, J, George, WD, Cuzick, J. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362:95–102.CrossRefGoogle ScholarPubMed

Abe, O, Abe, R, Enomoto, K. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717.Google Scholar

Cohen, I, Azaria, R, Fishman, A. Endometrial cancers in postmenopausal breast cancer patients with tamoxifen treatment. Int J Gynecol Pathol. 1999;18:304–309.CrossRefGoogle ScholarPubMed

Baum, M, Buzdar, AU, Cuzick, J. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131–2139.Google ScholarPubMed

Goss, PE, Ingle, JN, Martino, S. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–1802.CrossRefGoogle ScholarPubMed

Coombes, RC, Hall, E, Gibson, LJ. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092.CrossRefGoogle ScholarPubMed

Mouridsen, H, Keshaviah, A, Coates, AS. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 2007;25:5715–5722.CrossRefGoogle ScholarPubMed

Crivellari, D, Sun, Z, Coates, AS. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol. 2008;26:1972–1999.CrossRefGoogle ScholarPubMed

Muss, HB, Berry, DA, Cirrincione, C. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007;25:3699– 3704.CrossRefGoogle ScholarPubMed

Chapman, JA, Meng, D, Shepherd, L. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst. 2008;100:252–260.CrossRefGoogle ScholarPubMed

Muss, HB, Woolf, S, Berry, D. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. J Am Med Assoc. 2005;293:1073–1081.CrossRefGoogle ScholarPubMed

Muss, HB, Berry, DA, Cirrincione, CT. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009;360:2055–2065.CrossRefGoogle ScholarPubMed

Fargeot, P, Bonneterre, J, Roche, H. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol. 2004;22:4622–4630.CrossRefGoogle Scholar

Crivellari, D, Bonetti, M, Castiglione-Gertsch, M. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Groups Trial VII. J Clin Oncol. 2000;18:1412–1422.CrossRefGoogle Scholar

Wils, JA, Bliss, JM, Marty, M. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group. J Clin Oncol. 1999;17:1988–1998.CrossRefGoogle ScholarPubMed

Fisher, B, Dignam, J, Wolmark, N. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89:1673–1682.CrossRefGoogle ScholarPubMed

Clarke, M, Coates, AS, Darby, SC. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008;371:29–40.Google ScholarPubMed

Giordano, SH, Duan, Z, Kuo, YF. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24:2750–2756.CrossRefGoogle ScholarPubMed

Elkin, EB, Hurria, A, Mitra, N. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006;24:2757–2764.CrossRefGoogle Scholar

Extermann, M, Balducci, L, Lyman, GH. What threshold for adjuvant therapy in older breast cancer patients?J Clin Oncol. 2000;18:1709–1717.CrossRefGoogle ScholarPubMed

Shayne, M, Culakova, E, Dale, D. A validated risk model for early neutropenic events in older cancer patients receiving systemic chemotherapy. Proc Am Soc Clin Oncol. 2007;25:9026.Google Scholar

,Polychemotherapy for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists'; Collaborative Group. Lancet. 1998;352:930–942.CrossRefGoogle Scholar

Fisher, B, Brown, AM, Dimitrov, NV. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifennonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8:1483–1496.CrossRefGoogle ScholarPubMed

Doyle, JJ, Neugut, AI, Jacobson, JS. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23:8597–8605.CrossRefGoogle ScholarPubMed

Lyman, GH, Shayne, M. Granulocyte colony-stimulating factors: finding the right indication. Curr Opin Oncol. 2007;19:299–307.CrossRefGoogle ScholarPubMed

Shayne, M, Culakova, E, Wolff, DA. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer. 2009;115:5319–5328.CrossRefGoogle ScholarPubMed

Citron, ML, Berry, DA, Cirrincione, C. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol. 2003;21:1431–1439.CrossRefGoogle Scholar

Jones, SE, Savin, MA, Holmes, FA. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24:5381–5387.CrossRefGoogle ScholarPubMed

Milano, MT, Zhang, H, Metcalfe, SK. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009; 115:601–608.CrossRefGoogle ScholarPubMed

Greenberg, PA, Hortobagyi, GN, Smith, TL. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197–2205.CrossRefGoogle ScholarPubMed

Rapiti, E, Verkooijen, HM, Vlastos, G. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24:2743–2749.CrossRefGoogle ScholarPubMed

Mouridsen, H, Chaudri-Ross, HA. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer. Oncologist. 2004;9:497–506.CrossRefGoogle ScholarPubMed

Giovanazzi-Bannon, S, Rademaker, A, Lai, G. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1994;12:2447–2452.CrossRefGoogle ScholarPubMed

Christman, K, Muss, HB, Case, LD. Chemotherapy of metastatic breast cancer in the elderly: the Piedmont Oncology Association experience. J Am Med Assoc. 1992;268:57–62.CrossRefGoogle ScholarPubMed

Kimmick, GG, Fleming, R, Muss, HB. Cancer chemotherapy in older adults – a tolerability perspective. Drugs Aging. 1997;10:34–49.CrossRefGoogle ScholarPubMed

Booth, CM, Clemons, M, Dranitsaris, G. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol. 2007;5:374–380.Google ScholarPubMed

Brown, WW, Davis, BB, Spry, . Aging and the kidney. Arch Intern Med. 1986;146:1790–1796.CrossRefGoogle ScholarPubMed

Anderson, S, Brenner, BM. Effects of aging on the renal glomerulus. Am J Med. 1986;80:435–442.CrossRefGoogle ScholarPubMed

Swedko, PJ, Clark, HD, Paramsothy, K. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med. 2003;163:356–360.CrossRefGoogle ScholarPubMed

Wynne, HA, Cope, LH, Mutch, E. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology. 1989;9:297–301.CrossRefGoogle ScholarPubMed

Norris, B, Pritchard, KI, James, K. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol. 2000;18:2385–2394.CrossRefGoogle Scholar

Martin, M, Ruiz, A, Munoz, M. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007;8:219–225.CrossRefGoogle ScholarPubMed

Carrick, S, Parker, S, Wilcken, N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2005;CD003372.

O';Shaughnessy, J, Miles, D, Vukelja, S. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812–2823.CrossRefGoogle Scholar

Albain, KS, Nag, SM, Calderillo-Ruiz, G. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26:3950–3957.CrossRefGoogle ScholarPubMed

Keefe, DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002;95:1592–1600.CrossRefGoogle ScholarPubMed

Seidman, AD, Fornier, MN, Esteva, FJ. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001;19:2587–2595.CrossRefGoogle ScholarPubMed

Geyer, CE, Forster, J, Lindquist, D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733– 2743.CrossRefGoogle ScholarPubMed

Perez, EA, Byne, JA, Isaac, W. Cardiac safety experience in 3127 patients (pts) treated with lapatinib [abstract]. Ann Oncol. 2006;17(suppl 9):70.Google Scholar

Miller, K, Wang, M, Gralow, J. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666– 2676.CrossRefGoogle ScholarPubMed

Scappaticci, FA, Skillings, JR, Holden, SN. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99: 1232–1239.CrossRefGoogle ScholarPubMed

Tralongo, P, Repetto, L, Di Mari, A. Safety of long-term administration of bisphosphonates in elderly cancer patients. Oncology. 2004;67: 112–116.CrossRefGoogle ScholarPubMed

Wilkinson, GS, Kuo, YF, Freeman, JL. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst. 2007;99:1016–1024.CrossRefGoogle ScholarPubMed

Ferrucci, L, Guralnik, JM, Studenski, S. Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report. J Am Geriatr Soc. 2004;52:625–634.CrossRefGoogle ScholarPubMed

Dittus, K, Muss, HB. Management of the frail elderly with breast cancer. Oncology. 2007;21:1727–1734; discussion 1737, 1740.Google ScholarPubMed

Singletary, SE, Allred, C, Ashley, P. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–3636.CrossRefGoogle ScholarPubMed

Horner, MJ, Ries, LAG, Krapcho, M. SEER cancer statistics review, 1975–2006. SEER Web site. Available at: http://seer.cancer.gov/csr/1975_2006/.

Chap, LI, Barshy, SH, Bassett, LW. Breast cancer: natural history and pretreatment assessment. In: Cancer Treatment. Philadelphia: W. B. Saunders; 2001:507.Google Scholar